Novartis announced it has entered into an agreement to acquire Tourmaline Bio Inc. (NASDAQ: TRML) for $48 per share in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE